<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200725048206N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-08-20</date_registration>
      <primary_sponsor>Ilam University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the effect of phenylephrine in cesarean section</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the comparative effect of hemodynamic changes due to prophylactic Prescription  of phenylephrine in three forms: bolus, subcutaneous and infusion in mothers with selective cesarean section under spinal anesthesia with marcaine</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-07-31</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>120</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/49869</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: After completing the baseline assessment, patients were divided into three intervention groups and one control group. Randomization was performed using the block method (with block size of 4 or 6 and allocation ratio of 1: 1). Block randomization is used to reduce bias and achieve equilibrium in allocating participants to the study groups. Random allocation concealment was performed using opaque sealed envelopes with random sequences. Random allocation sequence is done using a computer-generated Kendall and Smith random number table. These tables have random numbers in both row and column directions, usually up to 99 rows and columns, and row and column digits. The cells are placed in five-digit blocks next to each other and separately to facilitate its use. This step is performed by a statistician who is not part of the research team. The random allocation sequence was hidden in closed opaque envelopes so that participants were assigned to 4 groups, Blinding description: The anesthesiologist and other members of the treatment staff and participants in the study are informed but the researcher is not
As follows:
  Participants will be notified upon consent
According to the decision of the anesthesiologist, one of the intervention methods is selected and after the prescription, the researcher, who is not aware of the prescription method, starts recording the data.</study_design>
      <phase>3</phase>
      <hc_freetext>Hemodynamics of pregnant women under spinal anesthesia.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Bolus method: For patients who are going to receive bolus prophylactic phenylephrine (Beacon Pharmaceuticals Ltd) , 1.5 µ g / kg of phenylephrine is injected 1 to 2 minutes before anesthesia. If systolic blood pressure drops by 20% of basal systolic blood pressure, 50 µg of intravenous phenylephrine is given intermittently. In cases where the heart rate is less than 50 beats per minute, atropine (Darou Pakhsh Co) 0.5 mg is prescribed. Intervention 2: Intervention group 2: Infusion method: For patients who are going to receive  infusion prophylactic phenylephrine (Beacon Pharmaceuticals Ltd) , 0.15 g / kg / min phenylephrine is injected intravenously for 30 minutes 1 to 2 minutes before anesthesia . If systolic blood pressure drops by 20% of basal systolic blood pressure, 50 g of intravenous phenylephrine is given intermittently. In cases where the heart rate is less than 50 beats per minute, atropine (Darou Pakhsh Co) 0.5 mg is prescribed. In the infusion group, the drug is discontinued if the systolic blood pressure increases by more than 20% of baseline. Intervention 3: Intervention group 3: subcutaneous: For patients who are supposed to receive subcutaneous prophylactic phenylephrine (Beacon Pharmaceuticals Ltd) , 5 to 10 minutes before anesthesia, 5 mg of phenylephrine is injected into the deltoid site. In case of systolic blood pressure drop by 20%  the base of systolic blood pressure  is given alternately 50 µg of intravenous phenylephrine. In cases where the heart rate is less than 50 beats per minute, atropine (Darou Pakhsh Co) 0.5 mg is prescribed. Intervention 4: Control group: In patients in the control group who do not receive phenylephrine (Beacon Pharmaceuticals Ltd), in case of systolic blood pressure drop of less than 20% of baseline or less than 100 mm Hg, they receive µg/kg 1/5 of phenylephrine in bolus and STAT, and in case of drop again  the dose is repeated.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is I will publish after complete the entire study</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Majid Aftabi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tajarian Alley 1 , Tajarian St , Chalimar Town</address>
        <city>Ilam</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6931134573</zip>
        <telephone>+98 84 3222 1999</telephone>
        <email>majidaftabi73@gmail.com</email>
        <affiliation>Ilam University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Majid Aftabi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Chalimar Town , Tajarian St , Tajarian 1 Alley</address>
        <city>Ilam</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6931134573</zip>
        <telephone>+98 84 3222 1999</telephone>
        <email>majidaftabi73@gmail.com</email>
        <affiliation>Ilam University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Pregnant women
Term
Single pregnancy
Elective cesarean section candidate</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>35 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>History of hypertension (BP&gt; 140/90
Diabetes
Cardiovascular and cerebral disease
Recognized fetal anomaly
Any contraindication to spinal anesthesia
Mothers who are at the beginning of the labor phase</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Diagnosis</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Bolus method: For patients who are going to receive bolus prophylactic phenylephrine (Beacon Pharmaceuticals Ltd) , 1.5 µ g / kg of phenylephrine is injected 1 to 2 minutes before anesthesia. If systolic blood pressure drops by 20% of basal systolic blood pressure, 50 µg of intravenous phenylephrine is given intermittently. In cases where the heart rate is less than 50 beats per minute, atropine (Darou Pakhsh Co) 0.5 mg is prescribed.</i_keyword>
      <i_keyword>Intervention group 2: Infusion method: For patients who are going to receive  infusion prophylactic phenylephrine (Beacon Pharmaceuticals Ltd) , 0.15 g / kg / min phenylephrine is injected intravenously for 30 minutes 1 to 2 minutes before anesthesia . If systolic blood pressure drops by 20% of basal systolic blood pressure, 50 g of intravenous phenylephrine is given intermittently. In cases where the heart rate is less than 50 beats per minute, atropine (Darou Pakhsh Co) 0.5 mg is prescribed. In the infusion group, the drug is discontinued if the systolic blood pressure increases by more than 20% of baseline.</i_keyword>
      <i_keyword>Intervention group 3: subcutaneous: For patients who are supposed to receive subcutaneous prophylactic phenylephrine (Beacon Pharmaceuticals Ltd) , 5 to 10 minutes before anesthesia, 5 mg of phenylephrine is injected into the deltoid site. In case of systolic blood pressure drop by 20%  the base of systolic blood pressure  is given alternately 50 µg of intravenous phenylephrine. In cases where the heart rate is less than 50 beats per minute, atropine (Darou Pakhsh Co) 0.5 mg is prescribed.</i_keyword>
      <i_keyword>Control group: In patients in the control group who do not receive phenylephrine (Beacon Pharmaceuticals Ltd), in case of systolic blood pressure drop of less than 20% of baseline or less than 100 mm Hg, they receive µg/kg 1/5 of phenylephrine in bolus and STAT, and in case of drop again  the dose is repeated</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Blood pressure. Timepoint: Base and minutes 5 and 15 and 30 and 60 and 90 and 120. Method of measurement: Cardiac monitor machine and blood pressure meter.</prim_outcome>
      <prim_outcome>Heart rate. Timepoint: Base and minutes 5 and 15 and 30 and 60 and 90 and 120. Method of measurement: Cardiac monitor machine and pulse oximeter.</prim_outcome>
      <prim_outcome>Apgar score. Timepoint: Minutes 1 and 5. Method of measurement: Physical examination.</prim_outcome>
      <prim_outcome>Umbilical cord blood Paco2 test. Timepoint: After birth. Method of measurement: Laboratory instruments.</prim_outcome>
      <prim_outcome>Umbilical cord blood HCO3 test. Timepoint: After birth. Method of measurement: Laboratory instruments.</prim_outcome>
      <prim_outcome>Umbilical cord blood pH test. Timepoint: After birth. Method of measurement: Laboratory instruments.</prim_outcome>
      <prim_outcome>Umbilical cord blood Base excess test. Timepoint: After birth. Method of measurement: Laboratory instruments.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ilam University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-07-14</approval_date>
        <contact_name>Ethics Committee of Ilam University of Medical Sciences</contact_name>
        <contact_address>Ilam University of Medical Sciences Campus  , Banganjab, Research Blvd. , Ilam Ilam Ilam Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
